BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28245390)

  • 21. Correlation of expression levels of BLyS and its receptors with multiple myeloma.
    Ju S; Wang Y; Ni H; Wang X; Jiang P; Kong X; Zhong R
    Clin Biochem; 2009 Mar; 42(4-5):387-99. PubMed ID: 19028483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands.
    Quartuccio L; Salvin S; Fabris M; Maset M; Pontarini E; Isola M; De Vita S
    Rheumatology (Oxford); 2013 Feb; 52(2):276-81. PubMed ID: 22879463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
    Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Xu D; Roschke V; Wu Y; Baker KP; Hilbert DM
    Arthritis Rheum; 2003 Dec; 48(12):3475-86. PubMed ID: 14673998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of an anti-B lymphocyte stimulator monoclonal antibody B7 and its binding activity to myeloma and lymphoma cell lines.
    Sun J; Li Y; Yu M; Sun Y; Feng J; Shen B
    Hybridoma (Larchmt); 2006 Aug; 25(4):238-42. PubMed ID: 16934021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of CD40 expression by flowcytometry on outcome of patients with non-Hodgkin's lymphoma.
    Soliman MA; Fathy AA; Alkilani A; Abd El-Bary N; El-Bassal F
    Egypt J Immunol; 2009; 16(1):61-70. PubMed ID: 20726323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [BCL-2/IgH and IgH gene rearrangements in bone marrow mononuclear cells of patients with non-Hodgkin's lymphoma].
    Zhang XH; Liang Y; Wang GJ; Ruan EB; Fu R; Qu W; Liu H; Guan J; Song J; Wang HQ; Wu YH; Xing LM; Wang XM; Wang J; Li LJ; Shao ZH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):379-84. PubMed ID: 21518492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
    Armitage JO; Vose JM; Linder J; Weisenburger D; Harrington D; Casey J; Bierman P; Sorensen S; Hutchins M; Moravec DF
    J Clin Oncol; 1989 Dec; 7(12):1783-90. PubMed ID: 2585020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
    La DT; Collins CE; Yang HT; Migone TS; Stohl W
    Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z
    Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.
    Halpern WG; Lappin P; Zanardi T; Cai W; Corcoran M; Zhong J; Baker KP
    Toxicol Sci; 2006 Jun; 91(2):586-99. PubMed ID: 16517838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms].
    Xiao C; Su ZL; Wu QL; Gao HY; Fang JC; Xia ZJ; Guan ZZ
    Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):22-7. PubMed ID: 15796877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5-diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).
    Ohmachi K
    Int J Hematol; 2019 Aug; 110(2):131-146. PubMed ID: 31177376
    [No Abstract]   [Full Text] [Related]  

  • 35. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B; Gerber HP; Sapra P
    Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Distribution of CD8+CD28- T cells and CD3+CD56+ NKT cells in peripheral blood of patients with B-cell non-Hodgkin's lymphoma].
    Shi YX; Zhang XS; Liu DG; Guan ZZ; Jiang WQ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1437-42. PubMed ID: 15566652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BLyS expression and JNK activation may form a feedback loop to promote survival and proliferation of multiple myeloma cells.
    Xu G; Shen XJ; Pu J; Chu SP; Wang XD; Wu XH; Sun CJ; Zhang X; Zhu BL; Ju SQ
    Cytokine; 2012 Nov; 60(2):505-13. PubMed ID: 22850273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes.
    López P; Scheel-Toellner D; Rodríguez-Carrio J; Caminal-Montero L; Gordon C; Suárez A
    Rheumatology (Oxford); 2014 Dec; 53(12):2249-58. PubMed ID: 24942493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of B lymphocyte stimulator expression by curcumin in B lymphocyte via suppressing nuclear translocation of NF-κB.
    Huang G; Yang Y; Xu Z; Zhou P; Gong W; Li Y; Fan J; He F
    Eur J Pharmacol; 2011 Jan; 650(1):451-7. PubMed ID: 20950605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection.
    Fabris M; Quartuccio L; Sacco S; De Marchi G; Pozzato G; Mazzaro C; Ferraccioli G; Migone TS; De Vita S
    Rheumatology (Oxford); 2007 Jan; 46(1):37-43. PubMed ID: 16735452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.